遠大醫藥(00512.HK)引進全球創新先進心力衰竭治療系統
遠大醫藥(00512.HK)公布,集團與美國CoRISMA MCS Systems, Inc (「CoRISMA」)達成股權及產品戰略合作。集團將以1,200萬美元為代價取得CoRISMA約22.2%的股權,後續會進一步投入以獲得治療心力衰竭的創新醫療器械 CoRISMA系列產品在大中華區(包括中國大陸、香港、澳門、台灣)、汶萊、柬埔寨、印尼、老撾、馬來西亞、緬甸、菲律賓、新加坡、泰國和越南(統稱「授權地區」)的獨家開發、生產及商業化權益,並使相關產品能於授權地區上市。
CoRISMA產品為集團血管介入藥塗球囊、神經介入取栓支架、血管及心腔診斷設備、鐳射消融平台後,在精准介入領域取得的又一全球創新產品,是集團在打造國際領先的心腦血管精准介入診療平台重要佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.